. Author manuscript; available in PMC: 2020 Sep 25.

Published in final edited form as: Biol Blood Marrow Transplant. 2018 Jun 15;24(10):2133–2138. doi: 10.1016/j.bbmt.2018.06.009

Table 3:

Characteristics and conditioning regimens for patients who underwent HDT/ASCT

	No. patients

Total patients	51
Radiotherapy prior to conditioning	46 (90%)
Conditioning regimen
• BEAM/BEAC	29 (57%)
• IE + TBI	6 (12%)
• Cyclophosphamide + etoposide	2 (4%)
• Cyclophosphamide + etoposide + TBI	3 (6%)
• CBV	4 (8%)
• Melphalan	3 (6%)
• Other	4 (8%)

HDT/ASCT: high dose therapy/autologous stem cell transplant. CR: complete remission, PR: partial remission, SD: stable disease. BEAM: BCNU (carmustine), etoposide, ara-C (cytarabine), melphalan. BEAC: BCNU (carmustine), etoposide, ara-C (cytarabine), cyclophosphamide

IE: ifosfamide, etoposide. CBV: cyclophosphamide, BCNU (carmustine), VP-16 (etoposide).